Europe Blood Screening Market: Industry Overview and Forecast (2024-2030) Trends, Dynamics, Segmentation

  • Europe Blood Screening Market size was valued at US$ 550.347 Mn. in 2023 and the total revenue is expected to grow at 7.7% through 2024 to 2030.

  • Format : PDF | Report ID : SMR_1312

Europe Blood Screening Market Overview:

A blood screening is a procedure in which donated blood is tested for various infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of the market was due to increased blood donations, an increase in the incidence of infectious diseases, and government programs.


Europe Blood Screening Market report examines the market's growth drivers and segments (Conductive Material, Application, End-User, and Region). Data has been provided by market participants and regions. This market study takes an in-depth look at all of the significant advancements occurring across all industry sectors. To provide key data analysis for the historical period (2018-2022), statistics, infographics, and presentations are used. The report examines the Europe Blood Screening markets, Drivers, Restraints, Opportunities, and Challenges. This SMR report includes Europe Blood Screening investor recommendations based on a detailed analysis of the current competitive landscape of the Europe Blood Screening market.


COVID-19 pandemic on the Europe Blood Screening Market:

COVID-19 has harmed the GDP of all countries. The globalization and closure of non-essential industries have led to the global economic downturn. The decline in demand from Europe customers has led to the regional economic downturn and is not expected to recover soon fully.


Europe Blood Screening Market Dynamics:

Increasing awareness towards cardiovascular diseases

The increasing number of transfusion procedures is expected to be a major contributor to the growth of the European blood screening market. A rise in the number of complex surgeries performed, such as chemotherapy, heart surgery, and organ transplants, which necessitate a large number of blood samples, could boost the market.


Rising awareness about safe blood transfusions, as well as an increase in the incidence of infectious diseases, are expected to drive market growth in the coming years. Government regulations requiring all donors and blood donors to be tested for patient safety are expected to boost market growth.


Such guidelines regarding transfusion services provide a regulatory framework for blood transfusion manufacturers. European countries have approved blood tests for HIV, HBV, HCV, parvovirus 19, and other viruses. Blood transfusion services in Germany are regulated by the International Red Cross, the Code of International Society of Blood Transfusion, and the German Transfusion Act.


In France, French Blood Establishment (EFS) regulates the collection, processing, testing, and distribution of labile blood products. In Italy, the National Blood Center (NBC), a health service division, is responsible for coordinating the technical and scientific control of the blood system.


Europe Blood Screening Market


To get more Insights: Request Free Sample Report


Europe Blood Screening Market Segment Analysis:

Based on the product, the European blood test market is divided into reagents and instruments. Part of the reagents led the market in 2023. Reagents are required for ELISA, western blotting, and NAT testing. The increase in the acceptance of these tests has contributed to the high demand for reagents. Tools are expected to prove less demand than reagents as they are a one-time investment in blood tests due to their high cost and long shelf life.


Europe Blood Screening Market


By Technology, nucleic Acid Amplification Test (NAT), Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescence Immunoassay (CLIA), Next-Generation Sequencing (NGS), and western blotting are the different types of technology used in the market. In terms of revenue, the NAT segment led the market in 2023. Between 1999 and 2001, the NAT was first implemented in six European countries: France, Germany, Spain, Italy, the United Kingdom, and Switzerland. The first plasma test detects the Hepatitis C virus (HCV).


Because of lower screening costs, broader application areas, and an increasing number of chronic infectious diseases, ELISA is becoming increasingly popular, particularly in developing countries. It is widely used in the European region for the detection of HIV, HCV, and HBV and is recommended for general use.


Europe Blood Screening Market Regional Insights:

Geographically, the market is divided into U.K., Germany, France, Italy and Spain. In 2023, Germany held the largest market share and is expected to maintain its position during the forecast period. The regional market is expected to grow due to increased awareness about blood donation. The UK is expected to become the fastest growing market in the upcoming period of 2024-2030. The increase in the population and the rising awareness towards the adaptation of the latest technology in blood screen is responsible of the growth in the UK blood screening market.


According to the WHO, blood donations increased from 3.4% in 2008 to 3.6% in 2010. About 2 million people regularly donate blood in Germany. In France, NAT has been used voluntarily to increase specific protection against uninfected viruses, such as Hepatitis A Virus (HAV) and Parvovirus B19 (B19V).


The objective of this report is to present an in-depth analysis of the Europe Blood Screening Market to industry stakeholders. The report provides the recent trends in the Europe Blood Screening Market and how these factors will impact on new business investment and market enhancement during the forecast period. The report also provides an understanding of the potential of the Europe Blood Screening Market and the competitive structure of the market by analyzing market leaders, market fans, and regional players.


The quality and quantity data provided in the Europe Blood Screening Market report assist the readers to understand which market Conductive Materials, regions are expected to grow in value, market factors, and key opportunity areas, which will impact industry growth and predictable market growth with respect to time. The report includes the competitive status of key competitors in the industry and their recent developments in the Europe Blood Screening Market. The report also provides a comprehensive set of factors such as company size, market share, market growth, revenue, production capacity, and profits of key players in the Europe Blood Screening Market.


The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Europe Blood Screening Market is easy for a new player to gain an edge in the market, do they come and go in the market regularly if the market is dominated by a few players, etc.


The report also includes a PESTEL Analysis, which aids in the development of company strategies. Political factors that help in analyzing how much a government can impact the Market. Economic variables assist in the calculating economic performance drivers that can affect the Market. Analyzing the impact of the overall environment and the impact of environmental concerns on the Europe Blood Screening Market is aided by legal factors.


Europe Blood Screening Market

Market Size in 2023

USD 550.34 Mn.

Market Size in 2030

USD 925.01 Mn.

CAGR (2024-2030)


Historic Data


Base Year


Forecast Period


Segment Scope

By Product Type

  • Reagent
  • Instrument

By Technology

  • Nucleic Acid Amplification Test (NAT)
  • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
  • Next-Generation Sequencing (NGS)
  • Western Blotting


By Country

  • UK
  • Germany
  • Spain
  • Italy
  • France


Europe Blood Screening Market Key Players

  1. Roche Diagnostics (Switzerland)
  2. BioMerieux (France)
  3. Grifols (Spain)
  4. Siemens Healthcare (Germany)
  5. Nelson Labs (Belgium)
  6. Nordic Laboratories (UK)
  7. Unilabs (Spain)
  8. Eurofins Scientific (Luxmenbourg)
  9. DiaSorin (Italy)
  10. LocalPCR (UK)
  11. Wren Healthcare (UK)
  12. London Medical Laboratory (UK)
  13. Tempus600 (Finland)
  14. On Point Testing (Norway)
  15. Age Labs (Norway)

Frequently Asked Questions

The current market size of Europe Blood Screening market is estimated to be USD 550.34 Mn. in 2023.

  1. Scope of the Report
  2. Research Methodology
    • Research Process
    • Europe Blood Screening Market: Target Audience
    • Europe Blood Screening Market: Primary Research (As per Client Requirement)
    • Europe Blood Screening Market: Secondary Research
  3. Executive Summary
  4. Competitive Landscape
    • Market Share Analysis by Country in 2023(%)
      • UK
      • France
      • Italy
      • Spain
      • Germany
    • Europe Stellar Competition matrix
      • UK Stellar Competition Matrix
      • France Stellar Competition Matrix
      • Italy Stellar Competition Matrix
      • Spain Stellar Competition Matrix
      • Germany Stellar Competition Matrix
    • Key Players Benchmarking: - by Product, Pricing, Investments, Expansion Plans, Physical Presence, and Presence in the Market.
    • Mergers and Acquisitions in Industry: - M&A by Region, Value, and Strategic Intent
    • Market Dynamics
      • Market Drivers
      • Market Restraints
      • Market Opportunities
      • Market Challenges
      • PESTLE Analysis
      • PORTERS Five Force Analysis
      • Value Chain Analysis
  5. Europe Blood Screening Market Segmentation
    • Europe Blood Screening Market, by Product Type (2023-2030)
      • Reagent
      • Instrumental
    • Europe Blood Screening Market, by Technology (2023-2030)
      • Nucleic Acid Amplification Test (NAT)
      • ELISA
      • Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)
      • Next-Generation Sequencing (NGS)
      • Western Blotting
  6. Company Profiles
    • Key Players
      • Roche Diagnostics (Switzerland)
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Business Strategy
        • Key Developments
      • BioMerieux (France)
      • Grifols (Spain)
      • Siemens Healthcare (Germany)
      • Nelson Labs (Belgium)
      • Nordic Laboratories (UK)
      • Unilabs (Spain)
      • Eurofins Scientific (Luxmenbourg)
      • DiaSorin (Italy)
      • LocalPCR (UK)
      • Wren Healthcare (UK)
      • London Medical Laboratory (UK)
      • Tempus600 (Finland)
      • On Point Testing (Norway)
      • Age Labs (Norway)
  7. Key Findings
  8. Recommendations

Enquiry Before Buy

Request Sample PDF